(BNR) Brenntag SE - Overview

Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: XETRA (Germany) | Market Cap: 8.363m EUR | Total Return: 4% in 12m

Industrial Chemicals, Food Ingredients, Specialty Chemicals, Raw Materials
Total Rating 45
Safety 71
Buy Signal -0.04
Specialty Chemicals
Industry Rotation: -2.6
Market Cap: 9.72B
Avg Turnover: 20.8M
Risk 3d forecast
Volatility34.9%
VaR 5th Pctl5.96%
VaR vs Median3.51%
Reward TTM
Sharpe Ratio0.08
Rel. Str. IBD53.4
Rel. Str. Peer Group68.2
Character TTM
Beta0.068
Beta Downside0.075
Hurst Exponent0.600
Drawdowns 3y
Max DD44.66%
CAGR/Max DD-0.11
CAGR/Mean DD-0.23
EPS (Earnings per Share) EPS (Earnings per Share) of BNR over the last years for every Quarter: "2021-03": 0.63, "2021-06": 0.95, "2021-09": 1.09, "2021-12": 0.95, "2022-03": 1.61, "2022-06": 1.88, "2022-09": 1.65, "2022-12": 0.68, "2023-03": 1.4, "2023-06": 1.31, "2023-09": 1.06, "2023-12": 1.32, "2024-03": 0.97, "2024-06": 1.13, "2024-09": 1.14, "2024-12": 1.07, "2025-03": 0.986, "2025-06": 0.44, "2025-09": 0.86, "2025-12": -0.18, "2026-03": 0.6787,
EPS CAGR: -26.88%
EPS Trend: -83.7%
Last SUE: -0.38
Qual. Beats: 0
Revenue Revenue of BNR over the last years for every Quarter: 2021-03: 3132.5, 2021-06: 3470.1, 2021-09: 3738.2, 2021-12: 4041.7, 2022-03: 4533.1, 2022-06: 5061.2, 2022-09: 5100.5, 2022-12: 4734.5, 2023-03: 4527.1, 2023-06: 4256.6, 2023-09: 4088.3, 2023-12: 3943.1, 2024-03: 4002.6, 2024-06: 4176.3, 2024-09: 4068.8, 2024-12: 3989.7, 2025-03: 4071.9, 2025-06: 3869.4, 2025-09: 3718.2, 2025-12: 3512, 2026-03: 3662,
Rev. CAGR: -6.05%
Rev. Trend: -91.5%
Last SUE: -0.43
Qual. Beats: 0

Warnings

Below Avwap Earnings

Tailwinds

Confidence

Description: BNR Brenntag SE

Brenntag SE is a global market leader in chemical and ingredient distribution, headquartered in Essen, Germany. The company operates through two distinct divisions: Brenntag Essentials, which focuses on high-volume process chemicals, and Brenntag Specialties, which provides technical expertise and formulation support for performance-driven sectors like pharmaceuticals and nutrition.

The business model functions as a critical intermediary between large-scale chemical producers and fragmented end-users, offering value-added services such as custom blending, repackaging, and regulatory compliance. In the specialty chemicals distribution sector, companies benefit from high barriers to entry due to the technical complexity of handling hazardous materials and the logistical requirements of just-in-time delivery across diverse international markets.

For a deeper look into the companys valuation metrics and historical performance, consider reviewing the data on ValueRay.

Headlines to Watch Out For
  • Global chemical price volatility impacts gross profit per unit margins
  • Strategic separation of Essentials and Specialties segments unlocks shareholder value
  • Industrial demand fluctuations in Europe and China drive volume growth
  • Mergers and acquisitions strategy accelerates consolidation in fragmented distribution markets
  • Rising logistics and energy costs pressure operational EBITA margins
Piotroski VR-10 (Strict) 5.5
Net Income: 228.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.95 > 1.0
NWC/Revenue: 14.21% < 20% (prev 10.47%; Δ 3.74% < -1%)
CFO/TA 0.08 > 3% & CFO 947.4m > Net Income 228.2m
Net Debt (3.26b) to EBITDA (1.16b): 2.80 < 3
Current Ratio: 1.74 > 1.5 & < 3
Outstanding Shares: last quarter (144.4m) vs 12m ago -0.09% < -2%
Gross Margin: 18.55% > 18% (prev 0.22%; Δ 1.83k% > 0.5%)
Asset Turnover: 129.2% > 50% (prev 140.1%; Δ -10.83% > 0%)
Interest Coverage Ratio: 3.77 > 6 (EBITDA TTM 1.16b / Interest Expense TTM 153.3m)
Altman Z'' 3.24
A: 0.19 (Total Current Assets 4.93b - Total Current Liabilities 2.83b) / Total Assets 11.2b
B: 0.33 (Retained Earnings 3.75b / Total Assets 11.2b)
C: 0.05 (EBIT TTM 578.2m / Avg Total Assets 11.4b)
D: 0.56 (Book Value of Equity 3.73b / Total Liabilities 6.68b)
Altman-Z'' = 3.24 = A
Beneish M -2.84
DSRI: 1.17 (Receivables 2.83b/2.67b, Revenue 14.8b/16.3b)
GMI: 1.19 (GM 18.55% / 22.08%)
AQI: 1.01 (AQ_t 0.36 / AQ_t-1 0.36)
SGI: 0.91 (Revenue 14.8b / 16.3b)
TATA: -0.06 (NI 228.2m - CFO 947.4m) / TA 11.2b)
Beneish M = -2.84 (Cap -4..+1) = A
What is the price of BNR shares?

As of May 24, 2026, the stock is trading at EUR 57.50 with a total of 360,869 shares traded.
Over the past week, the price has changed by -3.23%, over one month by -1.40%, over three months by +11.48% and over the past year by +3.95%.

Is BNR a buy, sell or hold?

Brenntag SE has no consensus analysts rating.

Brenntag SE (BNR) - Fundamental Data Overview as of 23 May 2026
Market Cap USD = 9.72b (8.36b EUR * 1.1625 EUR.USD)
P/E Trailing = 36.6582
P/E Forward = 10.8578
P/S = 0.5665
P/B = 1.8949
P/EG = 1.138
Revenue TTM = 14.8b EUR
EBIT TTM = 578.2m EUR
EBITDA TTM = 1.16b EUR
Long Term Debt = 2.60b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 283.0m EUR (from shortTermDebt, last quarter)
Debt = 3.95b EUR (from shortLongTermDebtTotal, last quarter) + Leases 571.0m
Net Debt = 3.26b EUR (calculated: Debt 3.95b - CCE 696.0m)
Enterprise Value = 11.6b EUR (8.36b + Debt 3.95b - CCE 696.0m)
Interest Coverage Ratio = 3.77 (Ebit TTM 578.2m / Interest Expense TTM 153.3m)
EV/FCF = 17.72x (Enterprise Value 11.6b / FCF TTM 655.7m)
FCF Yield = 5.64% (FCF TTM 655.7m / Enterprise Value 11.6b)
FCF Margin = 4.44% (FCF TTM 655.7m / Revenue TTM 14.8b)
Net Margin = 1.55% (Net Income TTM 228.2m / Revenue TTM 14.8b)
Gross Margin = 18.55% ((Revenue TTM 14.8b - Cost of Revenue TTM 12.0b) / Revenue TTM)
Gross Margin QoQ = 12.89% (prev 9.82%)
Tobins Q-Ratio = 1.04 (Enterprise Value 11.6b / Total Assets 11.2b)
Interest Expense / Debt = 3.88% (Interest Expense 153.3m / Debt 3.95b)
Taxrate = 32.65% (48.0m / 147.0m)
NOPAT = 389.4m (EBIT 578.2m * (1 - 32.65%))
Current Ratio = 1.74 (Total Current Assets 4.93b / Total Current Liabilities 2.83b)
Debt / Equity = 0.88 (Debt 3.95b / totalStockholderEquity, last quarter 4.48b)
Debt / EBITDA = 2.80 (Net Debt 3.26b / EBITDA 1.16b)
Debt / FCF = 4.97 (Net Debt 3.26b / FCF TTM 655.7m)
Total Stockholder Equity = 4.33b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.00% (Net Income 228.2m / Total Assets 11.2b)
RoE = 5.27% (Net Income TTM 228.2m / Total Stockholder Equity 4.33b)
RoCE = 8.34% (EBIT 578.2m / Capital Employed (Equity 4.33b + L.T.Debt 2.60b))
RoIC = 4.89% (NOPAT 389.4m / Invested Capital 7.96b)
WACC = 5.06% (E(8.36b)/V(12.3b) * Re(6.22%) + D(3.95b)/V(12.3b) * Rd(3.88%) * (1-Tc(0.33)))
Discount Rate = 6.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -9.67 | Cagr: -0.44%
[DCF] Terminal Value 77.96% ; FCFF base≈621.6m ; Y1≈712.3m ; Y5≈1.05b
[DCF] Fair Price = 86.60 (EV 15.8b - Net Debt 3.26b = Equity 12.5b / Shares 144.4m; r=8.35% [WACC [floored]]; 5y FCF grow 14.95% → 2.50% )
EPS Correlation: -83.72 | EPS CAGR: -26.88% | SUE: -0.38 | # QB: 0
Revenue Correlation: -91.47 | Revenue CAGR: -6.05% | SUE: -0.43 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.06 | Chg30d=+2.20% | Revisions=+20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=1.15 | Chg30d=+11.69% | Revisions=+20% | Analysts=2
EPS current Year (2026-12-31): EPS=3.71 | Chg30d=+0.90% | Revisions=+56% | GrowthEPS=+65.5% | GrowthRev=+1.3%
EPS next Year (2027-12-31): EPS=4.23 | Chg30d=+2.23% | Revisions=+56% | GrowthEPS=+14.1% | GrowthRev=+2.1%
[Analyst] Revisions Ratio: +56%